We plan to focus on advancing our comprehensive pipeline in the near term, with a current priority on skin diseases. We aim to execute our comprehensive pipeline strategy for dermatology and rapidly build our leadership in this disease area. In the meantime, we also plan to advance our drug candidates for rheumatic, respiratory and digestive diseases.

We will continue to monitor the global scientific advances and medical needs for autoimmune and allergic diseases, and endeavor to ensure that our pipeline is in a leading position in China scientifically and we can continuously provide accessible medical solutions for patients.

We plan to continuously optimize our CMC quality system and improve production efficiency. In order to ensure the stability of the supply chain and further improve production efficiency, we will continue to procure quality raw materials from Chinese suppliers and develop high-density cell technology. We aim to further reduce the costs of production of biologic drugs and improve their accessibility.

While prioritizing internal R&D and commercialization demand, we plan to further enhance the utilization of our production capacity by retaining the manufacturing rights of drug candidates for which we may have established strategic collaborations. 

With respect to the commercialization of certain drug candidates, in particular, drug candidates indicated for diseases with patients located in vast, geographically dispersed areas,we plan to continue to strategically cooperate with established pharmaceutical companies that have extensive experience in chronic disease management and broad sales networks covering such areas. We believe that such strategic cooperation can improve the availability of our drugs in the fastest and most cost-effective manner. We also plan to utilize the abundant expert resources and networks of these established pharmaceutical companies to connect with participants in the drug sales and distribution chain, to set the stage for the commercialization of our forthcoming drugs. 

To maximize the commercial potential of our assets, we plan to explore opportunities for overseas commercialization for drug candidates that could have competitive advantages in the global market. We expect to cooperate with MNCs or pharmaceutical companies with established local sales networks to expedite the overseas clinical development, approval and commercialization efforts.

We intent to promote our drug candidates to potential business partners globally and have formed specific development plans, including target regions and collaboration strategies for several drug candidates.